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Abstract 
Acute myeloid leukemia (AML), the most prevalent acute leukemia in adults, is an aggressive 
hematological malignancy arising in hematopoietic stem and progenitor cells. With the 
exception of a few specific AML subtypes, the mainstays of treatment have not significantly 
changed over the last 20 years, and are still based on standard cytotoxic chemotherapy. As a 
result, clinical outcome remains poor for the majority of patients, with overall long term 
survival in the region of 20-30%. Recent successes in characterizing the genetic landscape of 
AML have highlighted that, despite its heterogeneity, many cases of AML carry recurrent 
mutations in genes encoding epigenetic regulators. Transcriptional dysregulation and altered 
epigenetic function have therefore emerged as exciting areas in AML research and it is 
becoming increasingly clear that epigenetic dysfunction is central to leukemogenesis in AML. 
This has subsequently paved the way for the development of epigenetically targeted 
therapies. In this review, we will discuss the most recent advances in our understanding of 
the role of epigenetic dysregulation in AML pathobiology. We will particularly focus on those 
altered epigenetic programs that have been shown to be central to the development and 
maintenance of AML in preclinical models. We will discuss the recent development of 
therapeutics specifically targeting these key epigenetic programs in AML, describe their 
mechanism of action and present their current clinical development. Finally, we will discuss 
the opportunities presented by epigenetically targeted therapy in AML and will highlight 
future challenges ahead for the AML community, to ensure that these novel therapeutics are 
optimally translated into clinical practice and result in clinical improvement for AML patients. 
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Introduction 
 
Acute myeloid leukemia (AML) is the most prevalent acute leukemia in adults and results from 
the transformation of primitive hematopoietic stem and progenitor cells (HSPC), leading to 
increased proliferation and impaired differentiation of immature myeloid progenitors 
[Gilliland et al., 2002].  The term AML encompasses multiple specific and clearly defined 
subtypes that are highly heterogeneous in terms of their genetics, biology and clinical 
behaviour, highlighting the requirement for specific therapies for each subtype. However, 
despite our increased understanding of AML pathogenesis, the mainstay of treatment for the 
majority of AML subtypes has not significantly changed and continues to be based on 
standard cytotoxic chemotherapy consisting of anthracyclines and cytarabine [Vardiman et 
al., 2009, Roboz, 2012]. Prognosis is influenced by a combination of cytogenetic and 
molecular features of the disease, together with clinical characteristics and the patient’s age. 
Although treatment outcomes have improved over the last 20 years for certain groups of 
patients and specific subtypes,  the overall outlook for the majority of patients remains dismal 
with only 20-30% of patients achieving long-term survival [Liesveld, 2012], further 
highlighting that standard chemotherapy has reached the ceiling of its effect and that novel 
therapies are urgently required. 
  
One of the main advances in our understanding of AML pathogenesis has been the 
observation that transcriptional dysregulation and epigenetic dysfunction are common and 
recurring themes in AML, as demonstrated by the frequent occurrence of mutations in 
epigenetic and transcriptional regulators across several subtypes of AML [Cancer Genome 
Atlas Research, 2013] [Table 1].  The term epigenetics was originally used to describe heritable 
changes in gene expression (phenotype) that were independent of DNA sequence alterations 
(genotype) [Waddington, 2012]. Lately the term has come to include the whole of chromatin 
biology as well as those processes which can alter gene expression without affecting DNA 
sequence, including the recently highlighted role of non-coding RNAs in gene expression 
[Berger et al., 2009]. However, in this review, we will focus on the role of posttranslational 
modifications (PTM) at both the DNA and histone level, as their role in AML pathogenesis is 
better understood and has already led to the development of novel therapeutics which have 
shown great promise in pre-clinical models [Daigle et al., 2011, Dawson et al., 2011, Zuber et 
al., 2011, Schenk et al., 2012, Daigle et al., 2013, Wang et al., 2013] as will be further 
discussed. 
  
Chromatin is a composite of DNA and its protein scaffold, whose basic structure is called the 
nucleosome core complex. Each nucleosome is composed of 2 copies of each of the 4 histone 
proteins (H2A, H2B, H3 and H4), forming an octamer with DNA wrapped around it. The 
accessibility of the transcriptional machinery to chromatin affects the level to which a gene is 
actively transcribed and historically chromatin has been thought to be present in 2 physical 
states, i.e. euchromatin or heterochromatin. While euchromatin is in a relaxed state and 
allows binding of proteins modulating gene expression, heterochromatin is in a more compact 
state and less permissive to access of the transcriptional machinery, thus facilitating gene 
repression [Dawson et al., 2012]. Posttranslational modifications of histone proteins appear 
to contribute to the physical state of chromatin, as they can modulate non-covalent 
interactions between DNA and histone proteins. For example, acetylation is thought to 
increase chromatin accessibility by altering the overall histone charge thereby weakening the 
DNA-histone interaction. Moreover, a variety of histone modifications provide direct and 
indirect binding sites to either additional epigenetic regulators or components of the 
transcriptional machinery, thus leading to changes in gene expression levels. Several histone 
modifications and their putative role in chromatin biology and regulation of gene expression 
have been described to date, including acetylation, methylation, phosphorylation and 
ubiquitination [Kouzarides, 2007]. These modifications are produced by specific enzymes (the 
so-called “epigenetic writers”) and removed by other enzymes, (the so-called “epigenetic 
erasers”). More recently, a third class of protein has been described that are able to recognise 
and bind to specific PTM of histones and to modulate transcription and other DNA-templated 
processes such as replication and DNA repair. These proteins are generically termed 
epigenetic “readers” [Dawson et al., 2012]. Thus, the “epigenetic code” is the dynamic result 
of a multi-stage process laid down by epigenetic writers and erasers, leading to alterations in 
chromatic accessibility and modulation of gene expression and other DNA-templated 
processes and mediated by epigenetic readers [Figure 1].  
 
DNA methylation occurs at the Carbon-5 position in cytosine nucleotides in the context of a 
5’-CpG-3’ dinucleotide. This process is dynamic and reflects the balance between active 
methylation, mediated by the two predominantly de novo DNA methyltransferases, DNMT3A 
and 3B, and the maintenance methyltransferase DNMT1 [Jones, 2012] and demethylation.  
Recently, the mechanisms of active cytosine demethylation have also been identified, with 
the TET (ten eleven translocation) family of DNA dioxygenases initially oxidising cytosine 
through a number of intermediates (hydroxyl-; hmC, formyl-; fC and carboxyl-cytosine-; caC) 
in reactions requiring oxygen, Fe(II) and -ketoglutarate. These intermediates are then 
further converted back to unmethylated cytosine through the base excision repair (BER) 
pathway via catalysis involving the enzyme thymidine DNA glycosylase (TDG) +/-  AID-APOBEC 
[Abdel-Wahab et al., 2013] .  The exact relationship between DNA methylation and 
transcription correlates with the position of the CpG dinucleotide within the genome, but in 
general, methylated cytosine (5mC), particularly in promoter CpG islands, associates with 
heterochromatin and with transcriptional repression [Jones, 2012]. Conversely, 5hmC is 
mostly associated with euchromatin and an increase in 5hmC has been documented at the 
transcriptional start sites of expressed pluripotent genes in ES cells [Ficz et al., 2011].  
Analogous to modifications of histones, 5mC is bound by specific methylbinding proteins, 
presumably to translate the DNA methylation signal, and growing evidence suggests that 
5hmC and possibly 5fC and 5caC, are functional intermediates that bind to a specific 
repertoire of proteins; although the identities of these proteins are only now becoming 
apparent [Takai et al., 2014]. 
Interestingly, a growing number of epigenetic writers and erasers acquire either activating or 
loss-of function mutations in AML, leading to the hypothesis that epigenetic dysfunction is 
central to AML pathogenesis. Targeting these epigenetic alterations can modulate the 
transcriptional programmes altered in AML, opening novel therapeutic windows in this 
aggressive cancer. Although the number of epigenetic regulators reported to be 
mutated/dysregulated in AML is fast growing [Table 1], in this review we will specifically focus 
on those epigenetic regulators that have already been demonstrated to be central to AML 
pathogenesis and whose therapeutic targeting has been shown to be effective in AML 
preclinical models, facilitating their progression into clinical trials. 
  
IDH1/2 mutations: Mechanisms leading to leukemogenesis and their therapeutic targeting 
 
Isocitrate dehydrogenases (IDHs) are responsible for the oxidative decarboxylation of 
isocitrate to α-ketoglutarate. Three different isoforms of the IDH protein are present in 
humans. IDH3 is a NAD+ dependent isoform localized in the mitocondrial matrix which plays 
a central role in aerobic energy production via the Krebs cycle. In contrast, the other 2 
isoforms (IDH1 and IDH2) are NADP+ dependent and similar to each other. They mediate 
other metabolic processes, including lipid metabolism and glucose sensing (IDH1) and 
oxidative respiration (IDH2) [Reitman et al., 2010]. Mutations in the genes encoding IDH1 and 
2 tend not to occur together in the same clone and, collectively, have been described in 10-
20% of AML, predominantly in cytogenetically normal cases [Mardis et al., 2009, Marcucci et 
al., 2010, Chotirat et al., 2012]. These alteration-of-function mutations result in proteins with 
neomorphic activity that show increased affinity for α-ketoglutarate and furthermore 
promote its subsequent reduction to 2-hydroxyglutarate (2-HG) [Ward et al., 2010]. 2-HG 
accumulates in leukemic cells where it acts as an “oncometabolite” due to its ability to 
interfere with the functions of epigenetic modifiers with catalytic activity that requires α-
ketoglutarate  as an enzymatic co-factor, including the TET family of methylcytosine 
dioxygenases [Xu et al., 2011] and the Jumonji-C (JmjC) domain-containing family of histone 
lysine demethylases [Chowdhury et al., 2011].  Respectively, this inhibition leads to increases 
in both DNA and histone methylation, thus linking mutations in metabolic enzymes to 
dysregulated transcriptional programmes in AML [Figueroa et al., 2010, Lu et al., 2012]. It is 
notable in this respect that IDH1/2 and TET2 mutations are also mutually exclusive in AML 
and as would be predicted by their functional phenocopy of each other, patients carrying 
these mutations show similar DNA methylation profiles [Figueroa et al., 2010]. Although 
several IDH1/2 mutations have been described in AML, they have all been found to be gain-
of-function mutations, strengthening their involvement in AML pathogenesis [Chotirat et al., 
2012]. However, the prognostic significance of IDH1/2 mutations in AML is still unclear as 
contrasting results have been published, with some series showing an association with 
adverse outcome and others with an improved outcome [Boissel et al., 2010, Paschka et al., 
2010, Thol et al., 2010, Green et al., 2011, Chotirat et al., 2012, Koszarska et al., 2013]. It is 
possible that their prognostic significance depends on the specific allele and the identity and 
combination of other compound mutations as well as patient variables such as age and 
fitness.   
The mechanisms by which IDH1/2 mutations promote leukemogenesis have been 
investigated in vitro and in vivo in different models and appear to be secondary to impaired 
hematopoietic differentiation and expansion of stem/progenitor cells [Figueroa et al., 2010, 
Lu et al., 2012, Losman et al., 2013]. Hematopoietic-specific IDH1 (R132H) conditional knock-
in mouse models result in marked myeloproliferation, but do not progress to overt AML, 
strongly suggesting that additional mutations are required for AML development. These mice 
display an expansion of their hematopoietic stem cells (HSC) and myeloid progenitor (MP) 
compartments, both in their bone marrow (BM) and spleens. Moreover the DNA methylation 
signature within their HSC and MP compartments showed significant similarities with that 
observed in AML patients carrying IDH1/2 mutations [Sasaki et al., 2012]. In consonance with 
these findings, a similar phenotype was demonstrated using a retroviral 
transduction/transplantation mouse model. Wild-type mouse BM cells retrovirally 
transduced with IDH1 mutant alleles fail to generate disease. However, ectopic over-
expression of the IDH1 mutant allele in HoxA9-immortalised BM cells, significantly shortens 
the latency of the resulting myeloproliferative like-myeloid leukemia [Chaturvedi et al., 2013]. 
Together, these results suggest that IDH1 mutations are key events in leukemogenesis, but 
additional genetic or epigenetic factors are required for AML transformation.  
Regardless of their exact role in leukemogenesis, the novel function of IDH1/2 mutant 
proteins has provided an ideal target for leukemia-specific therapies and the development of 
IDH1/2 inhibitors has therefore gained significant momentum over the last few years, with 
many such inhibitors currently being assessed in preclinical models. HMS-101 is a specific 
inhibitor of the IDH1 mutated protein which has been discovered via a computational drug 
screen using the ZINC library [Irwin et al., 2012]. HMS-101 is active in vitro against both mouse 
BM cells and primary human AML cells carrying IDH1 mutations [Chaturvedi et al., 2013], and 
more recently has been shown to specifically inhibit 2-HG production by mutant IDH1 in vivo, 
while simultaneously reducing proliferation and inducing differentiation in leukemic cells. 
These effects translated in a prolonged survival of IDH1 mutant leukemic mice treated with 
HMS-101 and await further confirmation in clinical trials [Chaturvedi et al., 2014]. Compounds 
targeting mutant IDH2 have also been studied in leukemia cell lines and primary AML samples 
[Losman et al., 2013, Wang et al., 2013] and were shown to reduce 2-HG production and lead 
to differentiation of leukemia cells in a mutant-specific manner. These effects correlated with 
global changes in DNA methylation/histone state and suggest the  induction of differentiation 
through alterations in the epigenetic state of mutant cells as a putative mechanism of action 
for these compounds [Kernytsky et al., 2014]. These data have led to the clinical development 
of AG-221, an oral, potent, reversible, and selective inhibitor of the mutant IDH2 protein. A 
phase 1 study of AG-221 (NCT01915498) in patients with advanced IDH2 mutant positive 
hematological malignancies is currently underway [Table 2] and very encouraging preliminary 
results have recently been reported [Stein et al., 2014]. AG-221 has been well tolerated and 
20/32 (62.5%) of subjects evaluable for efficacy have achieved an objective response, with 11 
complete responses (CR) and 8 partial responses (PR) documented. Moreover, 5 subjects have 
stable disease and still remain on the study drug. Responses may also be relatively durable, 
as complete remissions of up to 4.5 months have been observed. These responses were 
associated with induced differentiation of myeloblasts into mature forms, consistent with 
preclinical models and all responding patients demonstrated neutrophil recovery. Early 
results therefore recapitulate the response observed in preclinical models and further 
confirm that IDH inhibitors are likely to be incorporated in the specific management of AML 
patients with IDH mutations. 
 
LSD1: Its role in leukemogenesis and as a potential therapeutic target in AML 
 
First identified in 2004 [Shi et al., 2005], lysine specific demethylase 1 (LSD1) has emerged as 
a promising therapeutic target in multiple cancers, notably in AML [Berglund et al., 2008, 
Lokken et al., 2012, Schenk et al., 2012, Fiskus et al., 2014, Niebel et al., 2014]. Its main role 
is demethylation of H3K4me1/2 and H3K9me1/2 (although it can also demethylate non-
histone proteins such as DNMT1 and TP53) and LSD1 has been shown to dynamically affect a 
wide range of transcriptional programmes in a context-specific manner, acting either as a 
transcriptional repressor or activator [Metzger et al., 2005, Wang et al., 2007, Cai et al., 2011, 
Huang et al., 2007, Wang et al., 2009, Kerenyi et al., 2013]. Increased LSD1 expression has 
been reported in a variety of solid organ tumors, including bladder, lung and colorectal 
carcinomas and, also in myeloproliferative disorders, including chronic myeloid leukemia 
(CML), myelodysplastic syndromes and multiple sub-types of AML [Berglund et al., 2008, 
Hayami et al., 2011, Niebel et al., 2014]. LSD1 had been shown to be a component of an MLL 
super-complex associated with sites of active transcription [Nakamura et al., 2002], which led 
to the hypothesis that it might have a direct and functional role in MLL-driven 
leukemogenesis. Indeed, analysis of microarray data from 23 murine MLL leukemias initially 
revealed a significant correlation between LSD1 expression levels and clonogenic potential (a 
surrogate for leukemic stem cell (LSC) frequency) in methylcellulose-based plating assays 
[Harris et al., 2012]. LSD1 knockdown was shown to induce terminal differentiation of AML 
cell lines in vitro and resulted in significant decreases of clonogenic potential across multiple 
human cell lines, murine leukemias and primary samples with an MLL-rearrangement. Similar 
results were obtained in vivo, where LSD1 knockdown impaired LSC numbers and function, as 
evidenced by reduced engraftment efficiency in secondary recipient mice. Interestingly, the 
levels of global H3K4me2 remained unchanged upon LSD1 inhibition. However, further ChIP-
seq analysis of MLL-AF9 murine tumours suggested that overexpression (or ectopic 
expression) of LSD1 may exert its oncogenic function by affecting the H3K4me2 status of 
specific loci bound by the MLL-AF9 fusion. Thus, sh-RNA knockdown, or pharmacological 
inhibition of LSD1, can directly corrupt the oncogenic programme of MLL-AF9, whilst largely 
sparing global levels of H3K4me2. Similar findings have also been reported in a non-MLL 
leukemia context, where pharmacological inhibition of LSD1 was able to sensitise LSCs 
towards the pro-differentiation effects of all-trans-retinoic acid (ATRA) treatment, 
irrespective of PML-RARA status [Schenk et al., 2012]. Despite the great promise that these 
pre-clinical studies have shown, the possible side-effects of LSD1 inhibition in normal 
hematopoiesis have not been conclusively established. In one of these studies, treatment 
with LSD1 inhibitors at the required anti-leukemic doses resulted in severe anemia and 
impaired erythropoiesis [Harris et al., 2012]. This study and others have also shown that LSD1 
loss greatly impairs normal granulopoiesis, erythropoiesis and platelet production [Harris et 
al., 2012, Sprussel et al., 2012]. However, these effects were transient and reversible upon 
treatment discontinuation. The data from these pre-clinical studies strongly suggest that the 
efficacy of LSD1 inhibition as an AML treatment will be largely dependent on the subtype (e.g. 
MLL status) and may offer maximum benefits when used in combination with other 
compounds such as ATRA. Two phase 1 studies using compound GSK2879552 (NCT02177812) 
and ORY-1001 (EudraCT 2013-002447-29) in patients with AML are currently underway 
[Table 2] and will address these questions. 
 DOT1L: Its role in leukemogenesis and as a potential therapeutic target in AML 
 
Disruptor of telomeric silencing 1-like (DOT1L) is the only histone H3 lysine 79 (H3K79) 
methyltransferase in mammals. It was originally identified in yeast where its overexpression 
led to disruption of telomeric silencing, hence its name [Singer et al., 1998]. The H3K79 
methylation mark is normally associated with active transcription and H3K79 methylation has 
been proposed to be a critical histone modification regulating cell proliferation, as its genetic 
silencing leads to abnormal mitotic spindle formation and cell cycle arrest at the G1 phase 
[Kim et al., 2012]. DOT1L is known to interact with the phosphorylated C-terminal domain of 
actively transcribing RNA polymerase II (RNAPII) and through this interaction, DOT1L and 
subsequent H3K79 methylations are targeted to actively transcribed genes [Kim et al., 
2012].  Beside its effects on cell cycle, DOT1L appears to also play a role in DNA repair as 
methylated H3K79 serves as a docking site for the global genomic repair machinery [Tatum et 
al., 2011]. A crucial role for DOT1L during embryonic development has been demonstrated 
using germline Dot1l knockout mouse models. These embryos die between E10.5 and E13.5 
from a complete absence of erythropoiesis [Feng et al., 2010]. The role of Dot1l during later 
hematopoiesis is however less clear, as different conditional knockout models have been 
used. Ubiquitous deletion of Dot1l in 6 to 10 week-old mice using a ROSA26-Cre-ER 
recombinase leads to death secondary to severe anemia and BM hypocellularity [Jo et al., 
2011] and consistent findings have been published using a very similar model [Nguyen et al., 
2011]. However, conditional excision of Dot1l in the hematopoietic compartment with the 
Vav-Cre recombinase leads to a moderate-to-severe reduction in both red and white blood 
cells, but does not completely abrogate multi-lineage hematopoiesis, suggesting that DOT1L 
is not an absolute requirement for adult hematopoiesis [Bernt et al., 2011]. This is critical 
from a therapeutic perspective, as transformation of murine BM by MLL-fusion oncogenes 
was demonstrated to be absolutely dependent upon the presence of DOT1L [Chang et al., 
2010, Jo et al., 2011, Nguyen et al., 2011]. Taken together, these data suggest a differential 
therapeutic window for inhibition of DOT1L that could be exploited in the management of 
certain subtypes of AML. Moreover, recent studies confirm that MLL-driven leukemias (MLL-
AF9 and MLL-AF6) display abnormal H3K79me2 patterns on direct target genes of the MLL-
fusion proteins which are distinctive compared to other transcriptionally active loci within the 
same cell and to the same loci when expressed under physiologic conditions during normal 
hematopoiesis [Bernt et al., 2011, Deshpande et al., 2014]. This specific epigenetic mark of 
MLL-fusion targets might explain the non-physiological dependence of the MLL-fusion driven 
leukemogenic transcription program on H3K79 methylation and DOT1L. In support of this 
model, only those MLL-fusion target genes which are central to the transformation ability of 
MLL oncogenes, such as the HoxA cluster and the homeobox gene Meis1, were shown to be 
downregulated following loss of DOT1L and H3K79 methylation [Bernt et al., 2011, Nguyen et 
al., 2011]. These specific effects might be secondary to the fact that DOT1L directly interacts 
with several known partners of MLL-fusions [Okada et al., 2005, Zhang et al., 2006, Mueller 
et al., 2007], particularly the AF10 protein, and is therefore aberrantly recruited to gene 
targets of these MLL-fusions. Taken together, these studies provide support for a critical role 
of DOT1L in leukemogenesis driven by MLL-fusions and its therapeutic targeting by small 
molecule inhibitors.  
 
Several preclinical studies have been reported using DOT1L inhibitors which compete with S-
adenosyl methionine, the methyl donor required for the methyltransferase activity of DOT1L 
[Daigle et al., 2011, Daigle et al., 2013]. These studies have shown that the inhibitors 
specifically reduce H3K79 methylation marks in leukemic cells together with a reduction in 
the expression of MLL-fusions target genes [Figure 2]. These effects are linked to similar 
effects on proliferation and viability of MLL-rearrenged leukemias and similar effects were 
also reported in xenograft models of MLL-leukemias in vivo. Recently, preclinical models of 
AML associated with another leukemogenic fusion, NUP98-NSD1, have also been shown to 
be sensitive to small molecule inhibition with DOT1L inhibitors, suggesting more widespread 
roles in AML therapy [Deshpande et al., 2014]. Moreover, toxic effects were not observed on 
healthy mice thus suggesting that DOT1L chemical inhibition might be better tolerated than 
gene deletion, possibly as a result of incomplete inhibition, increased sensitivity of leukemic 
cells and/or methyltransferase-independent functions of DOT1L that are not targeted by the 
inhibitors. 
 
EPZ-5676, the most promising of all the DOT1L inhibitors tested in preclinical models, has now 
entered phase 1 clinical trials in patients with advanced hematological malignancies, including 
AML with MLL-fusions (NCT01684150) [Table 2]. Although the compound has some 
pharmacokinetic limitations, requiring continuous infusions of up to 28 days, it appears to be 
well tolerated and was shown to lead to inhibition of H3K79 methylation. Complete responses 
have been observed in a small number of patients and continued clinical investigation is (text 
was removed here) currently ongoing [Stein et al., 2014]. 
 
Targeting BRD4 and other bromodomain and extra-terminal (BET) proteins in AML  
 
The Bromodomain and Extra Terminal (BET) protein family of epigenetic readers are 
transcriptional adapter molecules that, in general, facilitate transcription [Florence et al., 
2001, Zeng et al., 2002, Wu et al., 2007]. They comprise BRD2, BRD3 and BRD4, which are 
ubiquitously expressed and also BRDT, whose expression is confined to the testes [Pivot-Pajot 
et al., 2003, Wu et al., 2007]. As their name would suggest they contain tandem N-terminal 
bromodomains, specialised epigenetic reader modules that bind to acetylated lysine residues 
of histone (and non-histone) proteins, mediating effects that can range from histone 
modifications to chromatin remodelling and ultimately leading to transcriptional activation 
[Taverna et al., 2007]. BET proteins are essential for cellular homeostasis, as evidenced by 
knockout mouse models demonstrating embryonic lethality [Houzelstein et al., 2002, Dey et 
al., 2003, Kanno et al., 2004, Wu et al., 2007, Shang et al., 2009]. Recently, they have also 
been implicated in transcriptional dysregulation in many cancer types, with BRD4 identified 
as a key player in AML [Dawson et al., 2011, Delmore et al., 2011, Mertz et al., 2011, Zuber et 
al., 2011, Herrmann et al., 2012, Loven et al., 2013, Stewart et al., 2013, Dawson et al., 2014, 
Fiskus et al., 2014, Fiskus et al., 2014].  BRD4 and other BET proteins have been shown to 
activate transcription through facilitating transcriptional initiation via binding to transcription 
factors such as NF-kB [Yang et al., 2005, Zou et al., 2014] and also by  their recruitment of the 
positive transcription elongation factor b (P-TEFb) complex that facilitates release of RNAPII 
from proximal promoter pausing and transcriptional elongation [Figure 3]. We and others 
have also demonstrated the binding of BET proteins to the “so-called” super elongation 
complex (SEC) and the polymerase-associated factor complex (PAFc), two complexes integral 
to the transforming ability of MLL-rearranged leukemias [Dawson et al., 2011, Dawson et al., 
2012]. BRD4 has also been identified as an important modulator of oncogene expression in 
multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) through similar transcriptional 
dysregulation [Loven et al., 2013].  
 In addition to their role in the control of transcriptional initiation and elongation, recent 
studies have also implicated BRD4 and BET proteins in the regulation of enhancer function, 
particularly large enhancers (commonly called stretch or super enhancers) that control a 
number of developmentally important genes, including oncogenes [Loven et al., 2013, 
Dawson et al., 2014]. From studies in cell lines and patient samples, a number of genes critical 
for the maintenance of the leukemic phenotype, including BCL-2, IRF8 and c-MYC, have been 
identified as BET/BRD4 dependent and their downregulation upon inhibition with either the 
JQ1 or I-BET small molecule BET inhibitors leads to cell cycle arrest and apoptosis. 
Furthermore a significant survival advantage has been demonstrated for treated animals in 
murine models of aggressive MLL-rearranged leukemias [Dawson et al., 2011, Zuber et al., 
2011]. Although initial efficacy and mechanism was demonstrated in MLL-rearranged 
leukemias, small molecule BET inhibitors have since been used successfully in in vitro and in 
vivo studies against a wide range of non-MLL-driven AMLs, including those that carry 
mutations in nucleophosmin (NPM1), FLT3-ITD and DNMT3A genes [Stewart et al., 2013, 
Dawson et al., 2014, Fiskus et al., 2014], strengthening the notion that c-MYC inhibition is not 
the sole mechanism through which these compounds exert their anti-tumour potency. For 
NPM1c mutant AML, our own data predict that mutation of NPM1 may relieve an inhibitory 
interaction between wild-type NPM1 and BRD4, through the known cytosolic dislocation of 
both NPM1c and, via hetero-dimerization, wild type NPM1. This would then allow BRD4 to 
activate aberrant transcription at critical loci in NPM1c AML, explaining the sensitivity of this 
subtype to BET inhibition [Dawson et al., 2014]. However, for the majority of other AML 
subtypes, the exact mechanisms of action remains to be elucidated, as does the relative 
contribution of inhibition of transcriptional initiation, elongation and enhancer function to 
overall BET inhibitory function. Most importantly, BRD4 expression can be seen both in the 
cytoplasm and in the nuclei of LSCs coming from multiple AML primary samples (as well as 
AML cell lines), irrespective of the sub-type or disease stage [Herrmann et al., 2012], 
suggesting that BRD4 may be directly involved in the transcriptional programmes that control 
LSC potential, and thus, its inhibition may target the population that is mainly responsible for 
disease dissemination.  
 
Taken together with promising results from combination treatment studies in which BET 
inhibitors were used together with FLT3 tyrosine kinase inhibitors [Fiskus et al., 2014], 
conventional cytostatic compounds (e.g. ARA-C) [Herrmann et al., 2012] and histone 
deacetylases (HDAC) inhibitors [Fiskus et al., 2014], inhibition of BRD4/BET proteins has 
emerged as a therapeutic option in the future of AML treatment.  This has led to the 
introduction of number of early phase dose escalation safety studies using different BET 
inhibitors that are currently underway [Table 2]. The most mature of these, utilizing the 
OTX015 inhibitor (NCT01713582), recently reported no dose limiting toxicities in 28 patients 
at or below the maximum tolerated dose of 120mg daily [Dombret et al., 2014]. Of these 
patients, and with short follow up, 5 patients (18%) have demonstrated a clinically relevant 
response, with a sustained CR, one CR with incomplete platelet resolution and three PR. 
Interestingly, two of the five patients had an NPM1c mutation and four of the 5 patients poor 
risk characteristics (secondary or therapy related AML). Further clinical evaluation of BET 
inhibitors is ongoing and the results are eagerly awaited. 
 
Conclusions: opportunities and challenges ahead for AML epigenetic therapeutics 
 
Altered epigenetic regulation is a recurrent theme in AML and over the last 5-10 years a 
greater understanding of the processes underlying this has led to the identification of multiple 
rational therapeutic targets. Whilst these have provided new opportunities for the 
management of this unmet clinical problem, as evidenced by the evaluation of multiple 
epigenetic inhibitors in clinical trials, several questions remain to be answered before we can 
fully optimise and realise the promise of epigenetic therapies. The most prosaic of these are 
to recapitulate the safety and efficacy observed in preclinical studies in rigorous clinical trials. 
Another obvious question for these and indeed for all other AML therapies is how to identify 
and target the disease initiating and propagating compartment in each patient. The clonal 
architecture and hierarchy in individual AML patients is extremely complex and dynamic and 
has been described as a “moving target” due to clonal evolution. In view of this the use of 
different agents, potentially at different times, may be required to eradicate both the 
founding clone and all of its subclones, thereby achieving cure [Ding et al., 2012]. Moreover, 
genetically defined tumor subclones have been shown to possess unique phenotypic and/or 
functional properties that reflect some aspects of a tumor’s history and that may be able to 
predict its potential for relapse or resistance to therapy [Klco et al., 2014]. More recently, pre-
leukemic HSCs have been formally demonstrated in several AML patient samples. These cells 
are resistant to induction chemotherapy, persist at remission and presumably act as a 
reservoir from which relapse arises [Shlush et al., 2014]. These studies highlight further the 
need to target all clones in AML patients, with a particular focus possibly on those that may 
directly contribute to disease resistance/relapse, and accordingly the design of single agent 
and combinatorial trials must address effects on LSCs specifically.  
 
Many potentially useful agents are withdrawn from further development based on a lack of 
efficacy in early phase trials performed in relapsed patients, a patient group that is 
molecularly and cytogenetically heterogeneous and complex, as well as clinically very difficult 
to manage. In particular, epigenetic therapies, whose tempo of effect may be slower (cf the 
demethylating agent Azacytidine [Fenaux et al., 2009, Fenaux et al., 2010]) and that, due to 
their more targeted approach, may show efficacy only in specific AML subtypes, may be 
especially vulnerable to this false-negative assumption. Therefore, testing in newly diagnosed 
patients might be necessary to fully assess the efficacy of novel therapeutics, especially when 
these drugs have demonstrated minimal toxicity to normal hematopoiesis. Furthermore, the 
development of specific molecular and cellular predictive response biomarkers can help in 
identifying the appropriate patient groups in which to use specific therapies upfront, 
maximising their therapeutic response through their use in patients more likely to obtain 
clinical benefit. Therefore, as already applied in IDH1/2 trials, trial design should specifically 
target a clearly defined patient population that is most likely to benefit, based on the 
inhibitor’s mode of action. For other inhibitors with more pleiotropic effects (i.e. 
Bromodomain inhibitors), where these inhibitors have demonstrated potency across a 
range of AML subtypes, this personalised design is less important and trial entry should be 
more inclusive, although as it is also likely that some AML subtypes/genotypes will be more 
sensitive than others, trial design and analysis should  take account of this.   
Epigenetic therapies are unlikely to be effective in AML as single agents, therefore it is likely 
that they will need to be rationally combined with other therapies to achieve their maximal 
effect. Therefore, clarification of the timing, schedule and order of administration with 
combination partners for these therapies is extremely important. These combinations should 
be dictated by their mechanism of action, interactions and risk of combined toxicities with 
other standard and targeted therapies. Combination with a standard cytotoxic therapy at 
induction seems reasonable, as has successfully been used for BCR-ABL inhibitors in 
Philadelphia chromosome+ ALL [Fielding et al., 2014]. However epigenetically targeted 
therapies, which often lack a significant cytotoxic effect on their own but might have co-
toxicities with standard chemotherapy agents, might be particularly appealing as a prolonged 
treatment in the post-remission setting where they could target specific sub-clones once 
disease debulking has been achieved by the initial wave of standard cytotoxic treatment. This 
setting might also suit their potentially slower tempo of effect as alluded to previously. 
Although the majority of current trials focus on single agent treatment, there is a growing 
body of data from pre-clinical and mechanistic studies to predict which combinations are 
worth formally testing in AML patients. Finally, as the effects of epigenetic therapies are often 
seen over a prolonged period of time, novel biomarkers of response and schedules for 
monitoring, which could include evaluation of specific epigenetic marks, gene expression 
signatures and other biomarker levels, are likely to be needed to fully guide and assess the 
efficacy of these novel therapeutics. 
 
In conclusion, we are witnessing an exponential growth in our understanding of the role of 
altered epigenetics in AML biology. This in turn has led to the development of many novel 
therapeutics that suggest a step change in clinical practice. It is not unreasonable to predict 
that specific targeted epigenetic therapies will soon become available to individual patients, 
in a tailored-therapy approach, chosen in a bespoke manner based on their specific disease 
features. In addition, it is becoming increasingly probable that some of these novel agents 
will be utilised in the management of other hematological malignancies such as 
myelodysplastic syndromes and myeloproliferative disorders, as preclinical evidence of 
their efficacy in these conditions has been already demonstrated [Wyspianska et al., 2014].  
However, many challenges, such as further deconvoluting the complexity of a highly 
heterogeneous disease like AML, identifying and targeting the disease propagating reservoirs, 
as well as improving our ability to translate in meaningful clinical trials all the advances made 
in preclinical models, still need to be addressed and further investigated before these 
promising therapies lead to any significant clinical improvements for patients with AML and 
other hematological malignancies. 
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Table 1. Epigenetic regulators recurrently mutated in AML 
EPIGENETIC REGULATOR MUTATION TYPE EPIGENETIC 
SITE MODIFIED 
EPIGENETIC WRITERS   
DNA METHYLTRANSFERASE 
DNMT3A* 
 
DNA DIOXYGENASES 
TET2 
 
HISTONE METHYLTRANSFERASE 
KMT2A (MLL1)* 
 
KMT2C (MLL3)* 
KMT3B (NSD1)* 
NSD3 
KMT6 (EZH2) 
 
HISTONE ACETYLTRANSFERASE 
KAT3A (CBP)* 
 
 
 
KAT3B (EP300)* 
 
 
 
KAT6A (MOZ)* 
KAT6B (MORF)* 
 
Point mutation 
Indel 
 
Point mutation 
Indel 
 
Translocation (MLL-X) 
Partial Tandem Duplication 
Point mutation 
Translocation (NUP98-NSD1) 
Translocation (NUP98-NSD3) 
Point mutation 
Indel 
 
Translocation (MLL-CBP, MOZ-CBP) 
Point mutation 
 
 
Translocation (MOZ-EP300) 
Point mutation 
 
 
Translocation (MOZ-CBP, MOZ-TIF2) 
Translocation (MORF-CBP) 
 
5-mC 
 
 
5-hmC 
 
 
H3K4 
 
H3K4 
H3K36 
H3K36 
H3K27 
 
 
H3K18/K27 
 
 
 
H3K18/K27 
 
 
 
H3K14 
H3K14 
EPIGENETIC ERASERS   
HISTONE DEMETHYLASES 
KDM5A (JARID1A)* 
KDM6A (UTX) 
 
Translocation (NUP98-JARID1A) 
Point mutation 
 
H3K4 
H3K27 
METABOLIC ENZYMES   
ISOCITRATE DEHYDROGENASE 
IDH1 
 
 
 
IDH2 
 
Point mutation 
 
 
 
Point mutation 
 
5-mC 
H3K9 
H3K27 
H3K36 
5-mC 
H3K9 
H3K27 
H3K36 
All proteins marked with an* also contain reader domain(s) 
AML, acute myeloid leukemia; CBP, CREB binding protein; EZH2, enhancer of zest homolog 2; IDH, isocitrate 
dehydrogenase; JARID1A, Jumonji AT-rich interactive domain 1A; MLL, mixed lineage leukemia; MORF, MOZ-
related factors; MOZ, monocytic leukemia zinc finger; NSD, nuclear receptor binding SET-Domain ; NUP98, 
nucleoporin 98kDa; TET, ten-eleven translocation; TIF (NCOA2), nuclear receptor coactivator 2; UTX, 
ubiquitously transcribed tetratricopeptide repeat, X chromosome  
Table 2. Clinical trials of novel epigenetic therapies in AML from ClinicalTrials.gov as of December 2014* 
EPIGENETIC TARGET NCT/EudraCT NUMBER DRUG PHASE DISEASE 
STATUS 
Histone Demethylase inhibitors     
LSD1 
 
NCT02177812 
EudraCT 013-002447-29 
GSK2879552 
ORY-1001 
1 
1 
RL/RF 
RL/RF 
Histone Methylase inhibitors     
DOT1L 
 
NCT01684150 
NCT02141828  
EPZ-5676 
EPZ-5676 
1 
1 
RL/RF  
RL/RF-PEDS 
Bromodomain inhibitors     
BET proteins 
 
NCT02158858 
NCT01943851 
NCT01713582 
NCT02308761 
CPI-0610 
GSK525762 
OTX015 
TEN-010 
1 
1 
1 
1 
RL/RF 
RL/RF  
RL/RF 
RL/RF 
Metabolic enyzmes inhibitors     
IDH1 
IDH2 
NCT02074839 
NCT01915498 
AG-120 
AG-221 
1 
1 
RL/RF 
RL/RF /UT 
*only trials involving the targets discussed in the review are presented 
AML, acute myeloid leukemia; BET, bromodomain and extra-terminal domain family; DOT1L, disruptor of 
telomeric silencing 1-like; IDH, isocitrate dehydrogenase; LSD, lysine specific demethylase; NCT, National clinical 
trial; PEDS, pediatric;  RF, refractory; RL, relapsed; UT, untreated 
  
Figure Legends 
Figure 1.  Classification of epigenetic regulators 
Epigenetic regulators can be broadly divided in 3 groups. Epigenetic writers, such as 
mehyltransferases (e.g. EZH2) and acetyltransferases (e.g. CBP) are enzymes  responsible for 
covalently modifying histones by adding methyl (Me) or acetyl (Ac) groups to specific lysine 
residues. Epigenetic erasers, such as demethylases (e.g. LSD1) and histone deacetylases 
(HDAC), catalytically remove these histone marks. Finally, epigenetic readers are proteins 
which can recognise and selectively bind to specific covalent modifications of histones using 
highly specialised protein domains, such as plant homeodomain (PHD) finger and 
bromodomain (BRD). It should be noted that DNA does incur similar functional modifications 
although this is not represented in the figure. 
 
Figure 2. Model for the mechanism of action of DOT1L inhibitors 
The lysine methylase DOT1L is known to interact with several fusion partners of MLL 
translocations, such as AF4, AF9, AF10 and ENL. DOT1L interaction with AF9 leads to its 
aberrant recruitment to MLL-AF9 fusion target genes. At these target sites, DOT1L methylates 
lysine 79 of histone 3 (H3K79) using S-(5`-adenosyl)-l-methionine (SAM) as a donor of methyl 
(Me) groups.  H3K79 methylation is known to be an activating mark which facilitates 
transcription of MLL target genes (A). EPZ-5676 mimics SAM binding to DOT1L leading to 
inhibition of its methylase activity, reduction of H3K79 methylation at MLL-AF9 target genes 
and transcriptional suppression of MLL-AF9 oncogenic programme (B).  
 
Figure 3. Model for the mechanism of action of BET proteins inhibitors  
The aminoterminal domain of MLL proteins, which is usually preserved in MLL fusions such as 
MLL-AF9, physically interacts with the polymerase-associated factor complex (PAFc), while 
several MLL fusion partners are part of the superelongation complex (SEC) which also includes 
the positive transcription elongation factor-b (PTEFb), composed of CDK9 and cycline T1 or 
T2. The SEC-PTEFb complex phosphorylates (P) RNA polymerase II (RNA POL II) facilitating 
transcriptional elongation. BRD4 is a BET protein known to physically interact with both PAF 
and SEC-PTEFb and to bind acetyl lysine residues (Ac) on histones. As a result BRD4 specifically 
targets the SEC-PTEFb complex to active chromatin leading to transcription of MLL fusion 
target genes and activation of an oncogenic transcriptional programme (A). Upon treatment 
with bromodomain inhibitors (BRD INH), this interaction is inhibited and the transcription of 
MLL fusions target genes interrupted thus explaining the activity of BRD INH in preclinical 
models of MLL fusions leukemias (B). 
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